TABLE 3.
In vitro activity of the new fluoroquinolones and ciprofloxacin against anaerobes
| Bacteria | Fluoroquinolones | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ciprofloxacin | Clinafloxacin | Gatifloxacin | Grepafloxacin | Levofloxacin | Moxifloxacin | Sparfloxacin | Trovafloxacin | |||||||||
| MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | MIC50 | MIC90 | |
| Bacteroides fragilis | 4 | 16 | 0.13 | 0.5 | 0.39 | 1.56 | 2 | 16 | 2 | 8 | 0.5 | 1 | 2 | 2 | 0.25 | 0.5 |
| B fragilis group | 8 | 32 | 0.06 | 0.25 | NA | NA | 4 | 8 | 2 | 16 | 0.25 | 1 | 2 | 4 | 0.5 | 1 |
| Clostridium difficile | 8 | 16 | 0.5 | 2 | 0.78 | 1.56 | 8 | 32 | 6.25 | 6.25 | 1 | 2 | 4 | 8 | 1 | 4 |
| Clostridium perfringens | 0.25 | 1 | 0.06 | 0.13 | 0.39 | 0.39 | 0.5 | 1 | 0.2 | 0.39 | 0.5 | 0.5 | 0.25 | 1 | 0.12 | 0.25 |
| Fusobacterium species | 1 | 4 | 0.06 | 0.5 | NA | 0.39 | 1 | 8 | 0.25 | 4 | 0.12 | 0.5 | 1 | 2 | 0.25 | 2 |
| Peptostreptococcus species | 1 | 2 | 0.06 | 0.5 | NA | 3.13 | 1 | 2 | 0.5 | 2 | 0.12 | 0.25 | 0.25 | 0.5 | 0.06 | 0.5 |
National Committee for Clinical Laboratory Standards approved and tentative breakpoints (85): anaerobes – trovafloxacin ≥8 μg/mL is resistant; no data are available for others. MIC50 Minimum inhibitory concentration of 50% of isolates; MIC90 Minimum inhibitory concentration of 90% of isolates; NA Information not available. Adapted from references: ciprofloxacin 10,54,86–90; clinafloxacin 10,52,54,91,92; gatifloxacin 56–58,92; grepafloxacin 59,89,92; levofloxacin 83,93,94; moxifloxacin 68–70,90,95; sparfloxacin 14,54,57,58,75,88,92,93; trovafloxacin 10,45,47,83,86,87,92